94 patents
Utility
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibiting
18 Jan 24
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an FcγR that activates a cellular effector (“FcγRActivating,” such as FcγRIIA or FcγRIIIA) and an FcγR that inhibits a cellular effector (“FcγInhibiting,” such as FcγRIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such FcγR for the Fc region of the wild-type immunoglobulin.
Jeffrey B. Stavenhagen, Scott Koenig
Filed: 7 Sep 23
Utility
LAG-3-binding molecules and methods of use thereof
2 Jan 24
The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies.
Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
Filed: 12 Jan 21
Utility
Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
14 Dec 23
CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
Filed: 20 Mar 23
Utility
Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
12 Dec 23
The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”).
Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
Filed: 13 Jan 21
Utility
Compound Targeting IL-23A and Tnf-alpha and Uses Thereof
30 Nov 23
The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof.
Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
Filed: 6 Mar 23
Utility
Covalent Diabodies and Uses Thereof
30 Nov 23
The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers.
Leslie S. Johnson, Ling Huang
Filed: 6 Feb 23
Utility
Multi-chain polypeptide-containing tri-specific binding molecules
21 Nov 23
The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes.
Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
Filed: 13 Mar 20
Utility
PD-1-BINDING Molecules and Methods of Use Thereof
9 Nov 23
Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
Filed: 24 Feb 23
Utility
Bispecific CD16-binding molecules and their use in the treatment of disease
24 Oct 23
The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”).
Gundo Diedrich, Liqin Liu, Hua Watson Li, Leslie S. Johnson
Filed: 6 Dec 18
Utility
Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting
17 Oct 23
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an FcγR that activates a cellular effector (“FcγRActivating,” such as FcγRIIA or FcγRIIIA) and an FcγR that inhibits a cellular effector (“FcγRInhibiting,” such as FcγRIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such FcγR for the Fc region of the wild-type immunoglobulin.
Jeffrey B. Stavenhagen, Scott Koenig
Filed: 29 May 20
Utility
Methods for the Use of a PD-1 X CTLA-4 Bispecific Molecule
5 Oct 23
The present invention is directed in part to dosing regimens for administering a PD-1×CTLA-4 bispecific molecule for the treatment of cancer, and other conditions.
Bradley James SUMROW, Ezio BONVINI, Sharad SHARMA, Jon Marc WIGGINTON, Alexey Yevgenyevich BEREZHNOY
Filed: 23 Jul 21
Utility
B7-H3 Directed Antibody Drug Conjugates
31 Aug 23
The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey).
Deryk T. LOO, Ling HUANG, Leslie S. JOHNSON, Thomas SON, Juniper A. SCRIBNER, Ezio BONVINI
Filed: 6 Jan 23
Utility
Methods for the Use of a B7-H3 Antibody-drug Conjugate Alone or In Combination
20 Jul 23
The present invention is directed to dosing regimens for administering a humanized anti-B7-H3 antibody conjugated to at least one duocarmycin moiety (a “B7-H3-ADC”) for the treatment of cancer, particularly a cancer associated with expression of B7-H3.
Gerry Chester BOHAC, Deryk LOO, Juniper A. SCRIBNER, Jon Marc WIGGINTON
Filed: 10 May 21
Utility
Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies
13 Jul 23
The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or hypomethylating agents.
Jan Kenneth Davidson, Sergio Rutella
Filed: 9 Jun 21
Utility
Tri-specific binding molecules that specifically bind to multiple cancer antigens
11 Jul 23
The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes.
Ezio Bonvini, Paul A. Moore, Jonathan C. Li, Leslie S. Johnson, Kalpana Shah
Filed: 28 Feb 20
Utility
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
27 Jun 23
The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRHI Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL I Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain.
Ezio Bonvini, Ling Huang, Chia-Ying Kao Lam, Gurunadh Reddy Chichili, Ralph Froman Alderson, Paul A. Moore, Leslie S. Johnson
Filed: 13 Feb 19
Utility
Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
2 May 23
CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
Filed: 3 Mar 20
Utility
PD-1-binding molecules and methods of use thereof
11 Apr 23
The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies.
Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
Filed: 24 Jan 20
Utility
CD137 Binding Molecules and Uses Thereof
30 Mar 23
The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137, including antibodies, and molecules comprising epitope-binding fragments thereof The invention is further directed to multispecific binding molecules comprising one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g, a “CD137×TA Binding Molecule”).
Alexey Yevgenyevich BEREZHNOY, Gundo DIEDRICH, Paul A. MOORE, Ezio BONVINI, Kalpana SHAH
Filed: 16 Feb 21
Utility
B7-H3 directed antibody drug conjugates
28 Feb 23
The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey).
Deryk T. Loo, Ling Huang, Leslie S. Johnson, Thomas Son, Juniper A. Scribner, Ezio Bonvini
Filed: 17 Dec 20